Navigation Links
Onyx Pharmaceuticals Announces Plans to Amend Phase 3 FOCUS Study for European Registration
Date:3/28/2011

l program including 1st line multiple myeloma, combination studies, lymphoma and other malignancies.

About Multiple Myeloma

Multiple myeloma is the second most common hematologic cancer and results from an abnormality of plasma cells, usually in the bone marrow. In the United States, more than 50,000 people are living with multiple myeloma and approximately 20,000 new cases are diagnosed annually.(i) Worldwide, more than 180,000 people are living with multiple myeloma and approximately 86,000 new cases are diagnosed annually.(ii)

About Onyx Pharmaceuticals, Inc.

Onyx Pharmaceuticals, Inc. is a biopharmaceutical company committed to improving the lives of people with cancer. The company, in collaboration with Bayer HealthCare Pharmaceuticals Inc., is developing and marketing Nexavar® (sorafenib) tablets, a small molecule drug that is currently approved for the treatment of liver cancer and advanced kidney cancer. Additionally, Nexavar is being investigated in several ongoing trials in a variety of tumor types. Beyond Nexavar, Onyx has established a development pipeline of anticancer compounds at various stages of clinical testing, including carfilzomib, a selective proteasome inhibitor, that is currently being evaluated in multiple clinical trials for the treatment of patients with relapsed or relapsed/refractory multiple myeloma in various settings and solid tumors. ONX 0801, an alpha-folate receptor targeted inhibitor of thymidylate synthase, and ONX 0912, an oral proteasome inhibitor, are currently in Phase 1 testing. For more information about Onyx, visit the company's website at www.onyx-pharm.com.

Forward Looking Statements

This press release contains "forward-looking statements" of Onyx within the meaning of the federal securities laws.  These forward-looking statements include, without limitation, statements regarding the clinical development
'/>"/>

SOURCE Onyx Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Access Pharmaceuticals Appoints Industry Executive Anthony Mottola as Vice President of Managed Care and Market Access
2. VentiRx Pharmaceuticals Presents Positive Clinical and Pre-Clinical Data at American Academy of Allergy Asthma & Immunology Annual Meeting
3. Inovio Pharmaceuticals Enters Phase II Clinical Trial with SynCon™ DNA Vaccine for Cervical Dysplasia Caused by HPV
4. Anadys Pharmaceuticals Reports Fourth Quarter and Year-End 2010 Financial Results and Highlights
5. Endo Pharmaceuticals Appoints Dr. David Nash to Board of Directors
6. Cempra Pharmaceuticals to Present at the Cowen and Company 31st Annual Health Care Conference
7. Inovio Pharmaceuticals Foot-and-Mouth Disease DNA Vaccine Introduces Critical Advantages in Fight Against Most Serious Farm Animal Disease
8. MAP Pharmaceuticals Reports 2010 Fourth Quarter and Year End Financial Results
9. Idenix Pharmaceuticals Reports Fourth Quarter and Year End 2010 Financial Results
10. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2010 Financial Results on March 4, 2011
11. Anthera Pharmaceuticals to Present at the Citi 2011 Global Health Care Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2014)... About Bioactive Material Bioactive ... are increasingly becoming popular due to their ability ... having a negative impact on the human health. ... tissue repair materials in surgical procedures. Bioactive materials ... glass-ceramics, and composites. The major end-users of bioactive ...
(Date:9/23/2014)... 23, 2014 Kamal Rashid , ... Education and Training Center (BETC) and research professor of ... BioTalk 2014 , an international two-day event focused on ... by Global Summits, the event will bring together leaders ... cells to develop and produce human therapeutics. “The growth ...
(Date:9/23/2014)... 2014 This is a professional ... the Phenolic Resin industry in Global and China.The ... including definitions, applications and industry chain structure. Global ... provided with a focus on history, developments, trends ... between the international and Chinese situation is also ...
(Date:9/23/2014)... Erlab , the expert in ... and Burdinola, supplier of laboratory furniture solutions, announce a ... hood. , By integrating Erlab’s GreenFumeHood ... now offer an innovative solution utilizing the patented technology ... best-in-class detection technology, and communication for security and monitoring ...
Breaking Biology Technology:Global Bioactive Material Market 2014-2018 2Worcester Polytechnic Institute's Biomanufacturing Expertise to be Featured in Berlin 2Worcester Polytechnic Institute's Biomanufacturing Expertise to be Featured in Berlin 3Phenolic Resin Industry (International, China) Development Policy and Plan Now Available at ReportsnReports.com 2Erlab Partners with Burdinola to Deliver an Innovative Filtered Fume Hood 2
... N.J., May 9 Barr Pharmaceuticals,Inc. (NYSE: ... Laboratories,Inc., has received final approval from the U.S. ... Drug Application (ANDA) to,manufacture and market a generic ... contraceptive product manufactured and marketed,by Bayer Schering Pharma, ...
... May 9 Genaera,Corporation (Nasdaq: GENR ) today announced ... net loss for the quarter ended March 31,2008 was $4.3 ... a net loss of $4.2 million, or $(0.24) per basic ... Genaera,s research and development expenses for the quarter ended March,31, ...
... 9 Schering-Plough,Corporation (NYSE: SGP ) will hold ... Memphis, Tenn. At 8 a.m. (CDT) (9 a.m. EDT) ... be available to all interested,parties via the corporate Web ... Fred Hassan, Chairman and CEO, will report to,shareholders on ...
Cached Biology Technology:Barr Announces Approval of Generic Yasmin(R) 2Barr Announces Approval of Generic Yasmin(R) 3Genaera Corporation Announces First Quarter Financial Results 2Genaera Corporation Announces First Quarter Financial Results 3Genaera Corporation Announces First Quarter Financial Results 4
(Date:9/23/2014)... the effects of temperature on insects to predict how ... a Dartmouth study shows for the first time that ... ultimately limits how fast they grow. , "In other ... overall environmental conditions that shape the growth, survival and ... Lauren Culler , an Arctic postdoctoral researcher at Dartmouth. ...
(Date:9/23/2014)... scientists has identified a gene mutation that causes ... the bone marrow fails to produce normal amounts ... three generations had blood disorders, the researchers discovered ... chromosomal structures with crucial roles in normal cell ... suggest future molecular-based treatments that bypass the gene ...
(Date:9/23/2014)... 23, 2014 Research and Markets  has ... Forecast and Opportunities, 2019" report to their offering. ... for enhancing security and protection in private as well ... The country,s government is focusing on using biometric systems ... other national IDs that are of crucial importance to ...
Breaking Biology News(10 mins):Insects' fear limits boost from climate change, Dartmouth study shows 2Gene mutation discovered in blood disorder 2India Biometrics Market Forecast and Opportunities, 2019 2India Biometrics Market Forecast and Opportunities, 2019 3
... can be swallowed like a pill, injected through a ... to screen for, detect, and potentially treat, cancer and ... size in early development stages. They will also ... researchers at McMaster University will be escalating efforts to ...
... some teenagers taking common anti-depressants may become more aggressive ... the October Behavioral Neuroscience, which is published by the ... of Texas at Austin found that juvenile hamsters given ... the United States as Prozac, became more aggressive on ...
... not be necessary in the event of a large-scale ... a study led by researchers at Fred Hutchinson Cancer ... of Infectious Diseases. , Instead, the current U.S. government ... vaccination of hospital workers and close contacts would be ...
Cached Biology News:Nano-devices hold promise for early-stage cancer detection 2Nano-devices hold promise for early-stage cancer detection 3Adolescent but not adult hamsters are more aggressive on low dose of fluoxetine 2Mass vaccination unnecessary in the event of a large bioterrorist US smallpox attack 2Mass vaccination unnecessary in the event of a large bioterrorist US smallpox attack 3Mass vaccination unnecessary in the event of a large bioterrorist US smallpox attack 4Mass vaccination unnecessary in the event of a large bioterrorist US smallpox attack 5
... BR4i refrigerated multifunction centrifuges are equally capable of ... low sound level with a large range of ... rotor exchange system without tools ensures that the ... Instant rotor exchange (5 sec.) ...
... ,Each upright model provides fast pull-down, rapid ... for refrigerated blood. The BBR25 and BBR55 ... complete blood storage monitoring. Models BBR6, BBR11, ... HemaPro 101 alarm/monitor. All of these models ...
Sterile, individually wrapped, 4mm Cuvettes...
... form of Tobacco Etch Virus (TEV) protease ... significantly more stable than native TEV protease, ... recognizes a seven amino acid (Glu-Asn-Leu-Tyr-Phe-Gln-Gly, cleaving ... for removing affinity tags from fusion proteins ...
Biology Products: